DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

810 and management of end- stage CHF should be considered.
Under these circumstances, resource- intensive
treatment, including cardiac resynchronization therapy,
mechanical assist devices, high- risk surgical interventions,
and cardiac transplantation, may be considered.
Despite the numerous pharmacotherapeutic
advances outlined in this chapter, a poor prognosis
still remains for patients suffering from severe or
end- stage CHF. For these patients, the empathetic
initiation of end- of- life discussions may be useful in
order to establish appropriate treatment expectations
compatible with effective and patient- centered medical
care.
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
BIBLIOGRAPHY
Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology
of renin inhibitors: Implications for translational medicine
in hypertension, diabetic nephropathy and heart failure:
Expectations and reality. Biochem Pharm, 2009, 78:933–940.
AIRE (Acute Infarction Ramipril Efficacy) Study Investigators.
Effect of ramipril on mortality and morbidity of survivors of
acute myocardial infarction with clinical evidence of heart
failure. Lancet, 1993, 342:821–828.
Arai Y, Fujimori A, Sudoh K, et al. Vasopressin receptor antagonists:
Potential indications and clinical results. Curr Opin
Pharmacol, 2007, 7:124–129.
Bigger JT Jr. Diuretic therapy, hypertension, and cardiac arrest.
N Engl J Med, 1994, 330:1899–1900.
Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of
congestive heart failure and pulmonary artery catheterization
effectiveness: The ESCAPE trial. JAMA, 2005, 294:1625–1633.
Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al.
Myocardial- directed overexpression of the human β 1
-adrenergic
receptor in transgenic mice. J Mol Cell Cardiol, 2000,
32:817–830.
Braunwald E, Bristow MR. Congestive heart failure: Fifty years
of progress. Circulation, 2000, 102(suppl IV):14–23.
Bristow MR. β- Adrenergic receptor blockade in chronic heart
failure. Circulation, 2000, 101:558–569.
Bristow MR, Gilbert EM Abraham WT, et al. Carvedilol produces
dose- related improvements in left ventricular function
and survival in subjects with chronic heart failure. MOCHA
Investigators. Circulation, 1996, 94:2807–2816.
Bristow MR, Linas S, Port DJ. Drugs in the treatment of heart
failure. In: Zipes P, Libby P, eds. Braunwald’s Heart Disease:
A Textbook of Cardiovascular Medicine, 7th ed. Elsevier
Saunders, Philadelphia, 2005, pp. 569–601.
Brunton LL. A positive feedback loop contributes to the deleterious
effects of angiotensin. Proc Natl Acad Sci, 2005,
102:14483–14484.
Chan AK, Sanderson JE, Wang T, et al. Aldosterone receptor
antagonism induces reverse remodeling when added to
angiotensin receptor blockade in chronic heart failure. J Am
Coll Cardiol, 2007, 50:591–596.
Cohn JN. The management of chronic heart failure. N Engl J
Med, 1996, 335:490–498.
Cohn JN. Treatment of infarct related heart failure: Vasodilators
other than ACE inhibitors. Cardiovasc Drugs Ther, 1994,
8:119–122.
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator
therapy on mortality in chronic congestive heart failure.
Results of a Veterans Administration Cooperative Study. N Engl
J Med, 1986, 314:1547–1552.
Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure.
N Engl J Med, 1977, 297:254–258.
Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent
increase in mortality with vesnarinone among patients with
severe heart failure. Vesnarinone Trial Investigators. N Engl
J Med, 1998, 339:1810–1816.
Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril
with hydralazine–isosorbide dinitrate in the treatment of
chronic congestive heart failure. N Engl J Med, 1991, 325:
303–310.
Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical
progression in patients with mild symptoms of heart failure.
U.S. Carvedilol Heart Failure Study Group. Circulation,
1996, 94:2800–2806.
Communal C, Singh K, Pimentel DR, Colucci WS.
Norepinephrine stimulates apoptosis in adult rat ventricular
myocytes by activation of the β- adrenergic pathway.
Circulation, 1998, 98:1329–1334.
CONSENSUS Trial Study Group. Effects of enalapril on mortality
in severe congestive heart failure. Results of the
Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS). The CONSENSUS Trial Study Group. N Engl
J Med, 1987, 316:1429–1435.
Dargie HJ. Effect of carvedilol on outcome after myocardial
infarction in patients with left ventricular dysfunction: The
CAPRICORN randomized trial. Lancet, 2001, 357:1385–1390.
Dickstein K, Kjekshus J. Effects of losartan and captopril on
mortality and morbidity in high- risk patients after acute
myocardial infarction: The OPTIMAAL randomized trial.
Optimal Trial in Myocardial Infarction with Angiotensin II
Antagonist Losartan. Lancet, 2002, 360:752–760.
Doehner W, Rauchhaus M, Florea VG, et al. Urica acid in
cachectic and noncachectic patients with chronic heart failure:
Relationship to leg vascular resistance. Am Heart J, 2001,
141:792–799.
Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine
oxidase inhibition with allopurinol and endothelial function
and peripheral blood flow in hyperuricemic patients with
chronic heart failure: Results from 2 placebo- controlled
studies. Circulation, 2002, 105:2619–2624.
Doggrell SA. CHARMed— The effects of candesartan in heart
failure. Expert Opin Pharmacother, 2005, 6:513–516.
Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy
of high dose furosemide in severe heart failure: Bolus injection
versus continuous infusion. J Am Coll Cardiol, 1996,
28:376–382.
Drexler H, Hayoz D, Munzel T, et al. Endothelial function in
congestive heart failure. Am Heart J, 1993, 126:761–764.
Eichhorn EJ, Bristow MR. Medical therapy can improve the biological
properties of the chronically failing heart. A new era in
the treatment of heart failure. Circulation, 1996, 94:2285–2296.
Eichhorn EJ, Gheorghiade M. Digoxin— New perspective on an
old drug. N Engl J Med, 2002, 347:1394–1395.